Ikena Oncology Relocates HQ to 50 Northern Ave, Cuts Costs

TL;DR

**IKNA moving HQ to cut costs, trying to stretch cash.**

AI Summary

Ikena Oncology, Inc. filed an 8-K on January 17, 2024, to report that it is closing its office at 645 Summer Street, Suite 101, Boston, Massachusetts 02210, and relocating its principal executive offices to 50 Northern Ave., Boston, Massachusetts 02210. This move is part of a broader restructuring to reduce operating expenses and extend its cash runway. For investors, this matters because it signals the company is actively cutting costs, which could improve its financial stability and potentially extend the time before it needs to raise more capital, impacting stock valuation.

Why It Matters

This relocation and associated cost-cutting measures aim to improve Ikena Oncology's financial health by reducing operating expenses, which could extend its cash runway and potentially delay future equity dilution.

Risk Assessment

Risk Level: medium — While cost-cutting is positive, the need for such measures often indicates underlying financial pressures or a shift in strategic focus, which carries inherent risks for a biotech company.

Analyst Insight

A smart investor would monitor Ikena Oncology's upcoming financial reports for evidence of actual cost reductions and an extended cash runway, as these actions are critical for the company's long-term viability and could influence future stock performance.

Key Players & Entities

• Ikena Oncology, Inc. (company) — the registrant filing the 8-K
• 645 Summer Street, Suite 101, Boston, Massachusetts 02210 (location) — former principal executive offices
• 50 Northern Ave., Boston, Massachusetts 02210 (location) — new principal executive offices
• January 17, 2024 (date) — date of earliest event reported

Forward-Looking Statements

• Ikena Oncology will report reduced general and administrative expenses in its next quarterly filing due to the office relocation and cost-cutting. (Ikena Oncology, Inc.) — medium confidence, target: Q1 2024 Earnings Report

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share IKNA The Nasdaq
• $175 million — arketable securities were approximately $175 million as of December 31, 2023. These financia
• $1.6 million — hich aggregate charges of approximately $1.6 million relate to the Workforce Reduction. Expe

Filing Documents

• d459979d8k.htm (8-K) — 31KB
• d459979dex991.htm (EX-99.1) — 16KB
• g459979g0118225114764.jpg (GRAPHIC) — 2KB
• 0001193125-24-010227.txt ( ) — 183KB
• ikna-20240117.xsd (EX-101.SCH) — 3KB
• ikna-20240117_lab.xml (EX-101.LAB) — 19KB
• ikna-20240117_pre.xml (EX-101.PRE) — 12KB
• d459979d8k_htm.xml (XML) — 4KB

02

Item 2.02 Results of Operations and Financial Condition. On January 18, 2024, Ikena Oncology, Inc. (the "Company") announced that it estimates that its cash, cash equivalents and marketable securities were approximately $175 million as of December 31, 2023. These financial results are only preliminary estimates and are based on information available to management as of the date of this Current Report on Form 8-K and these estimates could change. The Company's actual financial results as of December 31, 2023 are subject to the completion of its financial statements as of and for such period. The Company's independent registered public accountants have not audited, reviewed or performed any procedures with respect to such preliminary estimates and accordingly, do not express an opinion or any other form of assurance with respect thereto. The Company's actual results for the year ended December 31, 2023 will be included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and may differ materially from the above estimate. The information contained in Item 2.02 of this Current Report on Form 8-K is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

05

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 17, 2024, the Board of Directors of the Company approved a plan to reduce the Company's workforce by approximately 35% (the "Workforce Reduction"). The Workforce Reduction is designed to align the Company's workforce with its strategy to focus on its clinical stage, targeted oncology programs, IK-930 and IK-595. The Workforce Reduction generally affects employees working in the Company's discovery organization, as well as select employees working in development and general and administrative functions. The Workforce Reduction will result in the termination of approximately twenty (20) employees and is expected to be completed by March 31, 2024. Following the Workforce Reduction, the Company expects to have approximately thirty-seven (37) full-time employees and to be appropriately resourced to continue executing its current strategy. The Company expects that the Workforce Reduction and focus on its clinical programs will result in a reduction of the Company's operating expenses and, based on its current operating plans, extends the Company's cash runway into the second half of 2026. The Company expects to incur exit costs related to the discontinuation of its discovery efforts and expects to recognize these charges during the three months ended March 31, 2024, of which aggregate charges of approximately $1.6 million relate to the Workforce Reduction. Expenses related to the Workforce Reduction consist of employee severance and related termination benefits, and are expected to result in approximately $1.6 million in cash expenditures.

01

Item 7.01 Regulation FD Disclosure. On January 18, 2024, the Company issued a press release announcing the Workforce Reduction. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01

Item 8.01 Other Events. As previously disclosed, the Company's AHR antagonist IK-175 and kynureninase IK-412 programs, in development in collaboration with Bristol Myers Squibb, were eligible for opt-in through early 2024. On January 17, 2024, Bristol Myers Squibb notified the Company of its decision not to opt-in on the IK-175 program. In addition, Bristol Myers Squibb did not provide an opt-in exercise for the IK-412 program. As a result, the Company has regained full global rights to the IK-175 and IK-412 programs. The IK-412 program remains IND ready. The Phase 1b study of IK-175 in urothelial carcinoma was completed and closed in 2023, and study data will be submitted for presentation at a future medical meeting. The Company will not invest further in the clinical development of IK-175 or IK-412 but will pursue strategic business development opportunities, including out-licensing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Ikena Oncology, Inc. Press Release, dated January 18, 2024 104 Cover Page Interactive Data File SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ikena Oncology, Inc. Date: January 18, 2024 By: /s/ Mark Manfredi Mark Manfredi, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR